A case is cited in which hydrallazine was used in conjunction with volume expansion as a novel approach to the improvement of orthostatic symptoms in a patient with idiopathic postural hypotension.
Introduction
Postural hypotension, whether isolated or associated with other neurological symptoms, such as the Shy-Drager syndrome, is a severely incapacitating and distressing condition. Therapy remains unsatisfactory and includes antigravity devices, aadrenoceptor agonists with or without monoamine oxidase inhibitors, and volume expansion with mineralocorticoids. Recent reports have indicated an unpredictable response to tyramine with monoamine oxidase inhibitors, and the hazard of iatrogenic supine hypertension (Nanda, Johnson and Keogh, 1976; Davies, Bannister and Sever, 1978) . A case is cited to illustrate the use of a therapeutic regime including the vasodilator hydrallazine which has provided subjective improvement in symptoms and objective evidence of enhanced orthostatic tolerance.
Case report
A 70-year-old man had experienced postural dizziness and blackouts for 4 years, and his BP had shown a marked postural drop with no change in heart rate. His therapy included elastic stockings, and oral administration of ephedrine and sustained release isoprenaline. There 
Comment
Therapy in idiopathic postural hypotension has been directed towards increasing cardiac output by chronotropic agents, or by influencing the effective circulating volume by means of arteriolar constriction and/or volume expansion. These manoeuvres result in minimal subjective and objective improvement-and often exacerbate the not infrequent supine hypertension. The present case study investigates a novel approach to improve orthostatic tolerance-involving volume expansion in association with a reduction in cardiac afterload effected by a decrease in arteriolar resistance. Cohn and Franciosa (1977) have described hydrallazine as producing its effect almost exclusively in the arterial bed; in the patient described, therefore, the reduced cardiac afterload, in conjunction with the increase in circulating volume produced by sodium supplementation and fluorocortisone, presumably results in improved cardiac output-but without producing supine hypertension. As a result of this increased output, venous return is increased, so that the tendency to a postural fall in BP is reduced. Hydrallazine (unlike some other vasodilators) does not cause venodilatation, and therefore does not have any adverse effect on cardiac preload. This indication for arteriolar vasodilator therapy is analogous to the role of vasodilators in the management of cardiac failure (Cohn and Franciosa, 1977) .
This single-blind, crossover hospital study resulted in subjective and objective patient improvement which was maintained during longer term outpatient management. Further controlled trials of this regime are therefore indicated. 
